Search results
Results from the WOW.Com Content Network
Otelixizumab, also known as TRX4, is a monoclonal antibody, [1] which is being developed for the treatment of type 1 diabetes and other autoimmune diseases. The antibody is being developed by Tolerx, Inc. in collaboration with GlaxoSmithKline and is being manufactured by Abbott Laboratories. [2] [3]
Teplizumab, sold under the brand name Tzield, is a humanized anti-CD3 monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes in people with stage 2 type 1 diabetes. [3] [4] [5] The Fc region of this antibody has been engineered to have Fc receptor non-binding (FNB) properties. [6]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Anti-cancer monoclonal antibodies can be targeted against malignant cells by several mechanisms. Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies. [18] In childhood lymphoma, phase I and II studies have found a positive effect of using antibody therapy. [19]
In one main study in adult patients with moderate to severe active Crohn's disease in whom conventional therapy or TNF-alpha antagonists were ineffective or could not be tolerated, vedolizumab was shown to be more effective than placebo: 15% (32 out of 220) of patients receiving vedolizumab showed improved symptoms after 6 weeks of treatment, compared with 7% (10 out of 148) of patients on ...
Newer monoclonal antibodies with the same mechanism of action include otelixizumab, teplizumab and visilizumab. They are being investigated for the treatment of other conditions like Crohn's disease , ulcerative colitis and type 1 diabetes , [ 1 ] and for inducing immune tolerance .
Zenocutuzumab, sold under the brand name Bizengri, is a humanized monoclonal antibody used for the treatment of non-small cell lung cancer or pancreatic cancer. [1] It is a low-fucose humanized full-length immunoglobulin G1 bispecific HER2- and HER3-directed antibody.
The US Food and Drug Administration (FDA) approved durvalumab for certain types of bladder, lung, and biliary tract cancer: [6] [13] [14]. Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within twelve months of neoadjuvant or adjuvant treatment with platinum ...